Scholarly article on topic 'Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India'

Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India Academic research paper on "Clinical medicine"

Share paper
Academic journal
Journal of Postgraduate Medicine
OECD Field of science

Academic research paper on topic "Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India"

ISSN 0022-3859

Impact Factor® for 2010:1.589

Official Publication of

The Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India



Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India

Maurya AK, Kant s, Nag vL1, Kushwaha RAs, Dhole TN1

Department of Pulmonary Medicine, Chhatrapati Shahuji Maharaj Medical University, (Erstwhile King George Medical College), department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Address for correspondence:

Dr. Surya Kant, E-mail: dr.kantskt@



Review completed Accepted

Background: Drug-resistant tuberculosis is one of major current challenges to global public health. The transmission of resistant strains is increasing as a burden of multidrug-resistant tuberculosis (MDR-TB) patients in extra pulmonary tuberculosis (EPTB) cases in India. Aim and Objectives: The aim was to study trends of antituberculosis drug resistance pattern in new cases and previously treated cases of EPTB in referral hospitals in northern India. Study Design and Setting: A prospectively observational study and referral medical institutions in northern India. Materials and Methods: All EPTB specimens were processed for Ziehl Neelsen staining, BACTEC culture and BACTEC NAP test for Mycobacterium tuberculosis complex. All M. tuberculosis complex isolates were performed for radiometric-based drug susceptibility pattern against streptomycin, isoniazid, rifampicin and ethambutol using the 1% proportion method. Results: We found that 165/756 (20.5%) isolates were identified as M. tuberculosis complex by the NAP test. We observed that 39.9% were resistant to firstline antitubercular drugs. The resistance rate was higher in previously treated patients: H (30.3%), R (16.3%), E (15.7%) and S (16.3%). MDR-TB was observed in 13.4%, but, in new cases, this was 11.4% and 19.1% of the previously treated patients (P<0.05). Conclusion: MDR-TB is gradually increased in EPTB cases and predominant resistance to previous treated cases of EPTB. The molecular drug sensitivity test (DST) method can be an early decision for chemotherapy in MDR-TB patients. The International Standards of TB Care need to be used by the RNTCP and professional medical associations as a tool to improve TB care in the country.


02-01-2012 KEYWORDS: Anti-tuberculosis drug, extrapulmonary tuberculosis, multidrug-resistant tuberculosis,

03-02-2012 Mycobacterium tuberculosis complex


uberculosis (TB) is one of the major public health problems in India. India has about 1.8 million new cases of TB annually, accounting for one-fifth of new cases in the world - a greater number than in any other country.[1,2] Drug-resistant tuberculosis (DR-TB) is a man-made problem, because of inadequate use of drugs, inappropriate prescription or poor adherence to treatment, which permits the multiplication of

Access this article online

Quick Response code:



drug-resistant strains.[3,4] The emergence of DR-TB strains is a global problem, which is a threat to the best efforts of prevention and TB control. The World Health Organization (WHO) reported that DR-TB is increasing in various parts of the world as well as in India.[5] The WHO and The International Union Against Tuberculosis and Lung Diseases has launched a Global Project on Anti-Tuberculosis Drug Resistance Surveillance, which uses standardized methods to measure the prevalence of drug resistance and assess its correlation with display of TB control.[6] Multidrug-resistant TB (MDR-TB), defined as resistance to at least rifampicin and isoniazid, has become a significant public health dilemma in a number of countries and an obstacle to effective global TB control.[7] Extrapulmonary TB (EPTB) is a significant health problem in both developing and developed countries.[8,9] Diagnosis of EPTB in its different clinical presentations remains a true major challenge.[10] Resistance with new cases results from direct transmission of DR Mycobacterium tuberculosis; resistance rates generally increase

when resistance among previously treated cases is already high and conditions for spread are favorable.[11] The Baltic region and countries of the former Soviet Union have reported the highest rates of MDR-TB in the world (approximately 10% in new and 25% in previously treated cases).[12] Recent reports from India state that MDR-TB has been found in 3% of new cases and 12% of previous treated patients.[13] Various studies have been focused on the pattern of drug resistance in pulmonary TB, but very few data is available for DR-TB in EPTB.[14-15] To the best of our knowledge, this is first study to report the patterns of anti-tuberculosis drug-resistance patterns among EPTB cases in northern India. The aim of the study to determine the antituberculosis drug resistance patterns and its trends in new cases and previously treated cases of EPTB cases in referral hospitals in northern India.

Materials and Methods

Settings: The study was conducted between July 2007 and December 2010 in two tertiary care referral medical institutions in northern India. The study was a prospective observational study. The study protocol was assessed and approved by the respective Institutional Ethics Review Boards.

Data Collection: The entire patient population was attending indoor (IPD) and outdoor (OPD) wards from two tertiary care centers in northern India. A written informed consent was obtained from the patients before enrollment into the study. The clinical history regarding present and past history of antitubercular treatment (ATT), family history of TB and any other associated disease was taken in the prescribed performa.

Sample Size: The sample size for the study was calculated by the formula proposed by Lemeshow et al.[16], where Z was equal to 1.96 (80% power of the study), the expected population proportional was 0.37, relative precision (%) was 20 and, at 95% confidence interval, the sample size for the study was 165 cases. Therefore, we have taken 165 strains of Mycobacterium tuberculosis complex (MTBC) from EPTB cases.

The formula for sample size calculation is as follows:

N = {Z2,- aJO - P) / €2 P

where, P: expected proportion, €: relative precision, a: significance level

Criteria for Inclusion: Patients included in the study were consenting new or previously treated EPTB cases patients from any age group in whom TB was confirmed by culture and in whom DST against MTBC strains had been performed. A flow chart of the inclusion criteria of MTBC isolates from EPTB cases in the study is presented in [Figure 1].

Non-consenting patients, those infected with Mycobacterium other than tuberculosis (MOTT) and bacillary patients with an unknown bacteriological profile were not included in the study, as were those patients not willing to participate in the study.

Figure 1: Flow chart of inclusion criteria of Mycobacterium tuberculosis complex isolates from extra pulmonary tuberculosis cases in the study

Definitions of Resistance Types: Resistance in new cases was defined as the presence of resistant strains of MTBC in patients who had never received anti-tuberculosis drugs or who had been treated for less than 1 month. Resistance in previously treated cases was defined as the presence of a resistant strain of MTBC in patients who had received anti-tuberculosis drugs in the past or who had been treated for more than 1 month.

Microbiological examination

Smear examination and culture: Specimens were processed for mycobacterial smear preparation and BACTEC culture. Smears were stained by the Ziehl Neelsen (ZN) method and examined for acid-fast bacilli (AFB).[17] Specimens from sterile sites were centrifuged and the sediment was inoculated into the BACTEC 12 B vial supplemented with the antimicrobial mixture PANTA (Becton Dickinson, Sparks, MD, USA). BACTEC vials were incubated at 37 ±1°C and interpreted as per Becton Dickinson manual instructions.[18] All inoculated BACTEC 12 B vials were tested twice a week for the first 3 weeks and then once a week for the remaining 3 weeks. Positive vials were subjected to smear microscopy for further confirmation. No growth after 8 weeks of incubation was treated as negative. Growth of MTBC was typed by niacin production, catalase activity at 68°C and pH 7 and susceptibility to P-nitrobenzoic acid.[19]

Biochemical identification of MTBC: The final identification of isolates belonging to MTBC was performed by the BACTEC NAP test (Becton Dickinson and Company, Sparks, MD, USA), where NAP (P-nitro-a-acetylamino-b-hydroxypropiophenone) was added to the culture to inhibit the growth of bacteria belonging to the MTBC.[18] Standard strain M. tuberculosis, H37Rv ATCCa no. 27294 was used as positive control.

Radiometric-based drug susceptibility test

Radiometric-based drug susceptibility testing of MTBC by the BACTEC 460 TB (Becton Dickinson and Company) system was carried out as per the manufacture's instructions.[18,20] First-line

drugs were provided in a drug kit (Becton and Dickinson). The following final concentrations were used: streptomycin (S) 6.0 mcg/mL, isoniazid (H) 0.1 mcg/mL, rifampicin (R) 2.0 mcg/mL and ethambutol (E) 7.5 mcg/mL. Briefly, 0.1 mL of the appropriate drug solution was injected into labeled BACTEC 12 B vials, which resulted in the desired concentration of a drug in the medium. This was followed by inoculation of 0.1 mL of bacterial suspension from a positive BACTEC 12B vial with a GI 500-800. For control, the bacterial inoculums were diluted 1:100 before inoculation. The inoculated 12 B vials were incubated and read daily on the instrument till the GI of the control reached >30. Reference strain of M. tuberculosis H37Rv was used as a quality control on a weekly basis.

Statistical analysis

All statistical calculations were performed using Statistical Package for Social Science (SPSS) Version 15.0. P<0.05 was considered statistically significant.


A total of 756 specimens from 756 patients with a presumptive clinical diagnosis of EPTB were evaluated for the presence of M. tuberculosis infection. Of the 756 specimens, 270 (35.8%) were lymph node aspirate and cold abscesses, 96 (12.7%) pleural fluid, 74 (9.8%) Cerebrospinal fluid, 73 (9.6%) urine, 50 (6.7%) biopsy materials, 47 pus (6.2%), 46 ascitic fluid (6.1%), 29 (3.9%) wound swabs, 19 (2.5%) gastric aspirate, 18 (2.3%) pericardial fluid, 17 (2.2%) synovial fluid and 17 (2.2%) bone marrow aspirates. Of the 756 specimens, 71 (9.3%) were positive for AFB by ZN staining and 227 (30.1%) were positive for mycobacteria by BACTEC culture. One hundred and sixty-five (20.6%) were confirmed as MTBC by the NAP test. Among 165 MTBC patients, the mean age of all patients was 32.12 + 5.23years; 94 (56.9%) were males and 71 (43.1%) were females, with 123 (74.5%) new cases (they had not taken ATT in the past or were less than 1 month on ATT) and 42 (25.5%) were cases as previous treated cases (they had taken ATT in the past or were more than 1 month on ATT) (P<0.05). The history of contact with TB patients was determined in 42 cases (25.4%); 19 (11.5%) were having a history of diabetic mellitus, family history of TB was present in 23 (13.9%) and three (1.8%) cases were HIV positive.

One hundred and sixty-five MTBC isolates were performed for first-line DST. Among the 165 MTBC isolates, 123 (74.5%) strains were seen in new cases and 42 (25.4%) strains were seen in previously treated cases of EPTB. We found that higher presence of resistant strains was seen in previous treated cases in comparison with new cases of EPTB (P<0.05). The resistance pattern of the 123 MTBC strains from the new cases is summarized in Table 1. Seventy-six (61.8%) were fully susceptible (SS), 44 (38.2%) were resistant and 14 (11.4%) were MDR-TB. The pattern of MDR-TB was five (4.1%) HR, three (2.4%) HR, three (2.4%) SHR and three (2.4%) HRES. The resistance pattern of 42 MTBC strains from previously treated cases is summarized in Table 1; 24 (57.2%) strains were SS and eight (19.1%) were MDR-TB. The pattern of MDR-TB was two (4.7%) HR, three (7.1%) SHR, three (7.1%) HRES and no

Table 1: Resistance pattern to first-line anti-tubercular drugs in new cases and previously treated cases (n=165)

Drug Cases Total

New cases Previously treated cases

Total test 123 (100) 42 (100) 165 (100)

Total full susceptibility (%) 76 (61.8) 24 (57.2) 100 (60.1)

Total resistance (%) 47 (38.2) 18 (42.8) 65 (39.9)

Monoresistance (%)

H 12 (9.7) 3 (7.1) 15

R 1 (0.8) 1 (2.3) 2

E 4 (3.2) 1 (2.3) 5

S 5 (4.1) 0 5

Total 22 (17.8) 5 (11.9) 27 (16.3)

Two-drug resistance (%)

SH 1 (0.8) 1 (2.3) 2

HR 5 (4.1) 2 (4.7) 7

HE 5 (4.1) 1 (2.3) 6

RS 2 (1.6) 0 2

Total 13 (10.5) 4 (3.2) 17 (10.3)

MDR-TB (%)

HR 5 (4.1) 2 (4.7) 7

HRE 3 (2.4) 0 3

HRS 3 (2.4) 3 (7.1) 6

HRES 3 (2.4) 3 (7.1) 6

Total 14 (11.4) 8 (19.1) 22 (13.4)

Three-drug resistance (%)

SHR 3 (2.4) 3 (7.1) 6

HRE 3 (2.4) 0 3

SHE 2 (1.6) 3 (7.1) 5

RES 1 (0.8) 0 1

Total 9 (7.3) 6 (14.3) 15 (9.1)

Four-drug resistance (%)

HRES 3 (2.4) 3 (7.1) 6

Total 3 (2.4) 3 (7.1) 6 (2.6)

resistant strains in HRE. Our results showed that 22 (17.8%) in monoresistance and 13 (10.5%) in two drug resistance were noted in the new cases, which was a higher percentage of resistant strains in comparison with the previously treated cases of EPTB (P>0.05). But, three drug resistance and four drug resistance of MTBC strains were higher presence of resistant strains in previously treated cases in comparison with the new cases of EPTB (P<0.05).

The resistance rate (RR) to first-line agent H, R, E and S in new cases, previously treated cases and overall RR was seen in 27.6%, 38.1% and 30.3%, 14.6%; 21.4% and 16.3%, 14.6%; 19.1% and 15.7% and 13.8%; 23.8% and 16.3%. Results are summarized in Table 2. Among the 23 MDR-TB strains with HIV association, three cases were HIV positive (13.1%) and 15 (65.2%) were negative, and five (21.7%) cases of HIV test were not performed due to unaccepted HIV testing (P<0.05). In the HIV and MDR-TB-positive cases, they had on-treatment of ART and ATT.

Table 2: Resistance rate for first-line anti-tubercular drugs according to new cases and previously treated cases

Drug Pattern Cases

New cases Previously treated cases

Isoniazid S 89 26

R 34 16

Total 123 42

RR 27.6% 38.1%

Overall RR 30.3%

Rifampin S 105 33

R 18 9

Total 123 42

RR 14.6% 21.4%

Overall RR 16.3%

Ethambutol S 105 34

R 18 8

Total 123 42

RR 14.6% 19.1%

Overall RR 15.7%

Streptomycin S 106 32

R 17 10

Total 123 42

RR 13.8% 23.8%

Overall RR 16.3%

S - Susceptibility; R - Resistance; % RR - Resistance rate (no. of resistant/total)


Our study confirmed that the high rate of drug resistance included MDR-TB among new cases and previously treated cases of EPTB at tertiary care hospitals in northern India. Overall, 39.9% of the EPTB cases had resistance to anti-tubercular drugs (38.2% of new cases and 42.8% of previously treated cases).

Gurang et al.[14] and Sachdeva et al.[15] have reported 10.5% from 513 EPTB patients in Nepal and 9.14% from 350 EPTB patients in India for LJ-based culture positivity of M. tuberculosis. In comparison, we found a 30.1% culture positivity of M. tuberculosis from 756 EPTB patients in northern India. We found a higher positive rate of M. tuberculosis due to use of liquid media for culture of mycobacteria in this study. Previous studies[21] revealed that the BACTEC system was found to be more advantageous in paucibacillary specimens, especially in case of extrapulmonary cases like cerebrospinal fluid, body fluids and fine needle cytology, where LJ media yielded very scanty growth or no growth.

Previous studies[14,15] have reported 88.9% of MTBC from Nepal and 62.5% presence of MTBC in EPTB specimens from India, but we found 72.6% of MTBC in EPTB specimens at tertiary care hospitals from northern India. We found that the maximum number of isolates in this study were isolates from lymph node aspiration. The findings are concordant with similar studies in other countries.[1415,22]

Earlier studies reported that the prevalence of MDR tuberculosis has been shown to vary widely over different regions, with the

higher rates being found in Nepal (48%), Gujarat, India (34%), New York city (USA) (30%), Brolivia (15%) and South Korea (15%).[23] As these results relate to pulmonary TB, comparisons are not strictly valid. Previous studies reported[1415] a high rate of MDR-TB in EPTB cases (12.5%) from Nepal and from Delhi (10%), India, but we found that the prevalence of MDR-TB was 13.5% in EPTB cases at our tertiary care hospitals in northern India. The reason for this high rate of MDR-TB may be that the highly suspected drug-resistant cases were considered for DST in our tertiary care referral center. The high frequency of chronic cases may explain the high resistance rate in previously treated cases. Patient who had received anti-tuberculous drugs in the past were significantly more likely to be drug resistant than those who had never received them (P<0.05). Overall, 39.9% strains were seen to be resistant in our study, although the percentage of new cases to monodrug resistance and two-drug resistance was seen to be higher in comparison with previous treated cases. Our results were similar to other studies reported from other regions,[24] which showed that the resistance rate to isoniazid was highest. There is rare and contracts with finding that have been published by other studies.[25-27] It remains to be seen whether this pattern will persist in the near future. A spurious result due to methodology error seems unlikely, as all the laboratory methods have remained unchanged and effective quality control has been maintained.

We found that rate of TB-HIV co-infection was high (13.1%) in MDR-TB patients. This supports the results of the study done by Gandhi et al.[28] and the WHO/IUATLD 2002-2007 (31.6%) Study.[29] The response to TB treatment is usually similar in patients with and without HIV, except that HIV patients have a greater risk of drug toxicity and of mortality during treatment.[30]

The limitations of the current study are that it contains potential biases that could limit the validity of the results, such as the methods of patient selection and data collection, including data related to treatment history, which was used to differentiate between new and previously treated cases. Other details about other predisposing factors for development of drug resistance may be missed, and clinical outcome of drug-resistant cases in each and every patient is not available. However, despite the possible limitations, the current study strongly suggests problems in the control of MDR-TB among EPTB in the tertiary care hospitals in northern India.

Radiometric-based drug susceptibility testing of MTBC by the BACTEC 460 TB system is based on modified proportional method and is FDA approved as first-line anti-TB drug.[21] This method is standardized to increases the accuracy of the results. We found that susceptibility results are available within 6-8 days compare with 2-4 weeks by LJ. This showed that we could report complete results of isolation, identification and drug susceptibility testing of isolate culture with an average of 4 weeks time, as recommended by the Center of Disease and Prevention Control.[20] Surveillance of MTBC drug susceptibility testing can guide verdict makers in important standardization procedures for chemotherapy and routine evaluation of the quality of the TB control programme.

Further molecular-based rapid MDR-TB screening tests that achieve a substantial reduction in diagnostic delay and early availability of DST results would benefit patients harboring MDR-TB with appropriate regimens. The impact of rapid assays on patient outcomes is highly dependent on the quality of the rest of the TB control program.

In conclusion, the prevalence of MDR-TB among EPTB has been increasing in northern India. The trend of MDR-TB in previously treated cases of EPTB cases has reached an alarming level. Circulating of MDR-TB strains within society is a serious problem. This fact should be kept in mind that one MDR-TB patient if left untreated or not treated properly will create another 10-15 new cases of MDR-TB within 1 year. There is an urgent need of surveillance programmes, and newer molecular DST tests can aid in the rapid detection of Rifampicin and Isoniazid, which can be used as molecular markers for MDR-TB. The early availability of DST results would be beneficial to patients harboring MDR-TB strains to enable them receive effective treatment with appropriate regimens.


This work was supported by a grant from the Indian Council of Medical Research, New Delhi (Extramural ICMR Project Sanction No. 5/8/5/4/2007-ECD-I). The authors would like to thank the Technical Members of the Mycobacteriology Laboratory, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India for their technical support during the research work.


1. TB Report. RNTCP Status Report Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi - 110001. Available from: http://www. [Last accessed on Sept 2010].

2. Steinbrook R. Tuberculosis and HIV in India. N Engl J Med 2007;356:1198-9.

3. Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938-40.

4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21.

5. World Health Organization. Anti-tuberculosis drug resistance in the world; Report no. 4; Geneva, Switzerland. WH0/HTM/TB/2008.394. Available from: TB_2008.394_eng.pdf. [Last accessed on 2010 Apr 05].

6. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-9.

7. Kant S, Maurya AK, Kushwaha RA, Nag VL, Prasad R. Multi-drug resistant tuberculosis: An iatrogenic problem. Biosci Trends 2010;4:48-55.

8. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004;38:199-205.

9. Cailhol J, Decludt B, Che D. Sociodemographic factors that contribute to the development of extrapulmonary tuberculosis were identified. J Clin Epidemiol 2005;58:1066-71.

10. Ehlers S, Ignatius R, Regnath T, Hahn H. Diagnosis of extrapulmonary tuberculosis by Gen-Probe amplified Mycobacterium tuberculosis direct test. J Clin Microbiol 1996;34:2275-9.

11. Sangare L, Diande S, Badoum G, Dingtoumda B, Traore AS. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int J Tuberc Lung Dis


12. Balabanova Y, Drobniewski F, Nikolayevskyy V, Kruuner A, Malomanova N, Simak T, et al. An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS One 2009;4:e7129.

13. Arova VK, Sarin R, Singla R, Kalhid UK, Mathuria K, Singla N, et al. DOTS-plus for patients with multidrug-resistant tuberculosis in India: Early results after three years. J Chest Dis Allied Sci 2007;49:75-9.

14. Gurung R, Bhattacharya SK, Pradhan B, Gurung S, Singh Y Phenotypic characterisation and drug sensitivity testing of mycobacteria isolated from extra-pulmonary tuberculosis. Kathmandu Univ Med J (KUMJ) 2010;2010:57-61.

15. Sachdeva R, Gardre DV, Talwar V. Characterization and drug susceptibility patterns of extra-pulmonary mycobacterial isolates. Indian J Med Res 2002;115:102-5.

16. Lemeshow S, Hosmer D, Klar J, Lwanga S. Adequacy of sample size in health studies. Unites States: John Wiley and Sons; 1990.

17. Baron EJ, Peterson LR, Finegold SM. Mycobacteria In: Nancy, editors. In Baily and Scott's Diagnostic Microbiology, 9th ed. St Luis: The CV Mosby Company; 1994. p. 590-33.

18. Siddiqui SH. BACTEC 460 TB system. Product and procedure manual. Sparks, MD: Becton Dickinson Microbiology System; 1996.

19. Kubica GP Differential identification of mycobacteria. VII. Key features for identification of clinically significant mycobacteria. Am Rev Respir Dis 1973;107:9-21.

20. Shinnick TM, Iademarco MF, Ridderhof JC. National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. MMWR Recomm Rep 2005;54:1-12.

21. Rodrigues CS, Shenai SV, Almeida D, Sadani MA, Goyal N, Vadher C, et al. Use of bactec 460 TB system in the diagnosis of tuberculosis. Indian J Med Microbiol 2007;25:32-6.

22. Ilgazli A, Boyaci H, Basyigit I, Yildiz F. Extra-pulmonary tuberculosis: Clinical and epidemiologic spectrum of 636 cases. Arch Med Res 2004;35:435-41.

23. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997;24 Suppl 1:S121-30.

24. Gupta PR, Singhal B, Sharma TN, Gupta RB. Prevalence of initial drug resistance in tuberculosis patients attending a chest hospital. Indian J Med Res 1993;97:102-3.

25. Hongthiamthong P Chuchottaworn C, Amatayakul N. Prevalence of drug resistance in Thai human immunodeficiency virus seropositive tuberculosis patients. J Med Assoc Thai 1994;77:363-7.

26. Hongthiamthong P Riantawan P Subhannachart P Fuangtong P Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: An experience from a Thai referral centre. J Med Assoc Thai 1994;77:520-5.

27. Riantawan P Punnotok J, Chaisuksuwan R, Pransujarit V Resistance of Mycobacterium tuberculosis to antituberculosis drugs in the Central Region of Thailand, 1996. Int J Tuberc Lung Dis 1998;2:616-20.

28. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.

29. Anti-Tuberculosis Drug Resistance in the World, Fourth Global Report; The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 2002-2007; p 53.

30. Asiimwe BB, Ghebremichael S, Kallenius G, Koivula T, Joloba ML. Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda. BMC Infect Dis 2008;8:101.

How to cite this article: Maurya AK, Kant S, Nag VL, Kushwaha R, Dhole TN. Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India. J Postgrad Med 2012;58:185-9.

Source of Support: Indian Council of Medical Research, New Delhi (Extramural ICMR Project Sanction No. 5/8/5/4/2007-ECD-I), Conflict of interest: None declared.